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Abstract
Background: Impaired glucose tolerance is a risk factor for atherosclerosis in hemodialysis
patients and renal transplant recipients.
Methods: To check the relationship of impaired glucose tolerance with the other atherosclerotic
risk factors, fasting blood sugar and the standard two hour glucose tolerance test, serum
tryglyceride, serum cholesterol, cyclosporine through level (in renal tranpslant recipients) and
hemoglobin A1C were measured in 55 stable renal transplant recipients, 55 hemodialysis patients
and 55 healthy controls with similar demographic characteristics. Patients with diabetes mellitus
and propranolol consumers were excluded. The mean age and female to male ratio were 39 +/- 7
years and 23/22, respectively.
Results: Four of the renal transplant recipients and twelve of the hemodialysis patients had
impaired glucose tolerance. Significant linear correlation was observed with body mass index and
IGT only in hemodialysis patients (r = 0.4, p = 0.05). Glucose tolerance also had a significant
correlation with triglyceride levels (217.2 +/- 55 mg/dl in hemodialysis patients vs. 214.3 +/- 13 mg/
dl in renal transplant recipients and 100.2 +/- 18 mg/dl in control groups, p = 0.001). The glucose
tolerance had significant relationship with higher serum cholesterol levels only in the renal
transplant recipients (269.7 +/- 54 in renal transplant recipients vs. 199.2 +/- 36.6 mg/dl in
hemodialysis and 190.5 +/- 34 mg/dl in control groups, p = 0.0001). In the renal transplant
recipients, a linear correlation was observed with glucose tolerance and both the serum
cyclosporine level (r = 0.9, p = 0.001) and the hemoglobin A1C concentration (6.2 +/- 0.9 g/dl).
The later correlation was also observed in the hemodialysis patients (6.4 +/- 0.7 g/dl; r = 67, p =
0.001).
Conclusions: We conclude that although fasting blood sugar is normal in non-diabetic renal
transplant and hemodialysis patients, impaired glucose tolerance could be associated with the other
atherosclerotic risk factors.
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Background
Mortality and morbidity due to cardiovascular diseases
are frequent in patients with diabetes mellitus and high
prevalence of diabetes and cardiovascular disease, also,
are observed in patients with end-stage renal disease
treated by renal replacement therapy, either renal trans-
plantation (RT) and dialysis [1]. Although uremia is typi-
cally associated with impaired glucose metabolism via
multiple mechanisms [2-4], hemodialysis improves,
although not completely, the uremic induced glucose
impairment [5-7]. Impaired glucose metabolism is also a
common and an important problem after RT. By improve-
ment of immunosuppression after RT, the incidence of
post transplant diabetes (PTDM) has been decreased from
41% to 2.5% [8,9]. Although we routinely screen and treat
only full-blown diabetes at the post transplant periods, an
overlooked aspect is the impaired glucose tolerance,
which may be a risk factor to induce atherosclerosis.
Impaired glucose tolerance de novo, may be a risk factor of
post-transplantation mortality and morbidity [10].
Although increased levels of glycosylated hemoglobin
(HbA1C) and lipid concentrations have been shown in
hemodialysis patients [11] and renal transplant recipients
[12] with diabetes, their impairment is not clear in the
both groups with impaired glucose tolerance without
apparent diabetes mellitus. In this study we investigated
glucose tolerance and lipid profiles in non-diabetic hemo-
dialysis and renal transplant patients.
Methods
We selected fifty five RT recipients with more than one
year of good renal allograft function (serum Cr < 1.5 mg/
dl), under conventional triple therapy composed of
cyclosporine A (CsA), azathiopurine and prednisolone.
Their allograft sources were living donors. Fifty five stable
HD patients and another fifty five healthy controls (C),
were also enrolled in this study. The mean age (39 ± 7
years), sex (F/M ratio was 33/22), body mass index (BMI)
24.7 ± 1.28 kg/m2) were similar in the three groups (see
table 1). Patients with diabetes mellitus and propranolol
consumers were excluded.
The levels of serum triglyceride, cholesterol (measured by
enzymatic spectrophotometry)[13], CsA (measured by
ELISA in whole blood, only in renal transplant recipients)
and glycosylated haemoglobin concentration (Hb A1c)
(measured by column chromatography) were measured
after 10 hours fasting (in the hemodialysis group, in the
early morning before hemodialysis). Fasting blood sugar
and the standard 2 hours glucose tolerance test (after
ingestion of 75 g of glucose) were detected in the three
groups by spectrophotometry. Statistical analysis was per-
formed by Kuruskal wallis, U-Mann Whitney, multiple
comparison and regression correlation coefficient tests,
using SPSS 10.05.
Results
On the basis of WHO classification [14], four of our
(7.5%) renal transplant recipients and twelve (22%) of
GTT has a linear relationship with BMI in hemodialysis  patients Figure 1
GTT has a linear relationship with BMI in hemodialysis 
patients. Impairment of GTT is more significant in the hemo-
dialysis patients with higher BMI. Gtt2 = glucose tolerance 
test at the second hours of 75 gr oral glucose. bmih = body 
mass index in hemodialysis patients
The glucose tolerance in the HD patients had a significant lin- ear correlation with the level of serum triglycerides Figure 2
The glucose tolerance in the HD patients had a significant lin-
ear correlation with the level of serum triglycerides. gttd1= 
glucose tolerance test in dialysis patients, tgh= serum con-
centration of triglyceride in hemodialysis patients.
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the hemodialysis patients had impaired glucose tolerance,
i.e. the 2 hour of glucose tolerance test was between 140
and 200 mg/dl. It was more obvious at the end of the sec-
ond hour of GTT. Although BMI was roughly similar in
the three groups (Table 1), a significant linear correlation
was observed between BMI and impaired glucose toler-
ance only in HD patients (r = 0.4, p = 0.05) (fig 1), but not
in the RT recipients. The glucose tolerance (especially at
the first hour) in the HD patients had a significant linear
correlation with the level of serum triglycerides (r = 0.87,
p = 0.001) (Fig 2). Serum triglyceride concentration was
217.2 ± 55 mg/dl in HD vs. 214.3 ± 13 mg/dl in RT and
100.2 ± 18 mg/dl in C groups, (p = 0.001). On the other
hand the four RT recipients with IGTT (i.e. 100% of RT
recipients with IGTT) had the higher serum cholesterol
levels (308.4 ± 24.4 mg/dl)) compared with the remain-
ing RT recipients with normal GTT (248.7 ± 55.6 mg/dl)
with p = 0.031 (table 2). The mean of serum cholesterol
was 269.7 ± 54 mg/dl in RT vs. 199.2 ± 36.6 mg/dl in HD
and190.5 ± 34 mg/dl in C groups (p = 0.0001). A linear
correlation was observed between impaired GTT and both
of the serum Cyclosporine level (r = 0.9, p = 0.001) and
HbA1c in RT recipients (Fig 3). The mean of HbA1c was
6.2 ± 0.6 gr/dl in the RT recipients with normal GTT vs.
4.34 ± 0.26 g/dl in the RT recipients with IGGT (p < 0.001,
table 2). The later correlation was also observed in HD
patients, in whom the mean of HbA1C level was 6.4 ± 0.7
gr/dl in the group (r = 67, p = 0.001). In contrast of a close
relationship of IGTT and higher HbA1c, the gender, age,
times after transplantation and BMI did not impact on
Cyclosporine level and HbA1c have correlations with the  IGTT in RT recipients Figure 3
Cyclosporine level and HbA1c have correlations with the 
IGTT in RT recipients ▲  = Serum Cyclosporine level ❍  = 
HbA1c concentration
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Table 1: Demographical, biochemical, hematological and therapeutical factors in hemodialysis patients and renal transplant recipients.
HD RT Control
Age (years) 48 ± 3 46 ± 4 47 ± 4
Male/female ratio 33/22 33/22 33/22
BMI (Kg/m2) 24.6 ± 1.4 23.8 ± 1.2 23.6 ± 1.3
Cholesterol (mg/dl) 199.2 ± 36.6 269.7 ± 54 190.5 ± 34
Triglycerides (mg/dl) 217.2 ± 55 214.3 ± 13 100.2 ± 18
HgA1C (g/dl) 6.42 ± 0.7 6.2 ± 0.9 5.7 ± 0.7
Hb level 10.9 ± 0.8 12.4 ± 1.1 13.3 ± 0.8
Therapy with vitamin D3 0.5 µg/day (number) 25 -- --
Impaired glucose tolerance (number) 12* 4** --
*Significant correlation with BMI, serum triglycerides and HgA1C
** Significant correlation with serum cholesterol, CysA concentration and HgA1CBMC Nephrology 2004, 5:11 http://www.biomedcentral.com/1471-2369/5/11
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IGTT in RT recipients. Although in logistic regression anal-
ysis higher serum level of cyclosporine was correlated with
increased GTT impairment, we could not evaluate the
implication of corticosteroids on this test, because all of
the 55 RT recipients were received prednisolone at a doses
of 5 to 10 mg/day.
Discussion
Impaired glucose tolerance occurs in about 50% of
patients with chronic renal failure (CRF) patients. It is due
to multiple factors, which the two most important of
them being insulin resistance at target organs and
impaired insulin secretion from the pancreas [15]. Insulin
sensitivity would be reduced by up to 60% in non-dia-
betic patients with CRF before dialysis [16]. Marked
improvement in insulin sensitivity and consequently
glucose tolerance has been reported in non-diabetic
patients after 10 weeks of HD, although they are not com-
pletely returned to normal [15]. Thereby, impaired glu-
cose tolerance during HD is secondary to non-effective
removable toxins by HD compared with peritoneal dialy-
sis. In the latter more effective removal of middle mole-
cule toxins causes better glucose tolerance, although
glucose rich dialyzet solution is used [16]. The other
causes of impaired glucose tolerance in HD patients may
be secondary to metabolic disturbances, such as anemia
[17], malnutrition [18] and vitamin D3 deficiency [19].
Although all of our HD patients had normochromic-nor-
mocytic anemia, the severity was not proportionate with
impaired glucose tolerance (The data has not been
shown). The patients were well nourished and were under
treatment with daily oral vitamin D3 (Rocaltrol), 0.5
micrograms per day. So malnutrition and vitamin D3
deficiency could not to contribute to impaired glucose tol-
erance in our HD patients. Impaired glucose tolerance was
also observed in 7.5% of our RT recipients. All of the pre-
sumed risk factors for post transplant diabetes mellitus
such as old age [18], family history of any known diabetes
mellitus in their first relatives[21], cadaveric allografts
[22] and obesity did not exist in the patients. Previously
Boudreaux et al. [23] reported that those patients who
weighed more than 70 kg had a higher incidence of post
transplant diabetes mellitus (PTDM). A relative risk of 1.4
for developing PTDM for every 10 kg increase in body
weight more than 60 kg has been shown [12]. Although in
our study obese patients (BMI > 30 kg/m2) were not
included in the both groups, a correlation was observed
between impaired glucose tolerance and higher BMI in
our HD patients. In RT recipients, the major risk factor for
impaired glucose tolerance was immunosuppressive ther-
apy. Through using higher doses of CsA and corticoster-
oids, PTDM was previously more common, but the
complication has been decreased to 2–5% in FK506-
based immunosuppressive protocols [24,25]. Although
this relatively uncommon complication is a major cause
of post-transplant mortality and morbidity, even minor
glucose intolerance is associated with an increased long-
term risk for cardiovascular disease [26]. The importance
of impaired glucose tolerance should not be underesti-
mated in these patients with high risk of atherosclerosis.
Hyperlipidemia, another risk factor for atherosclerosis, on
one hand accompanies the impaired glucose tolerance
observed in the HD and RT patients and on the other
hand increases the risk of atherosclerosis induced by
impaired glucose tolerance. As reported previously, a ten-
dency to higher pre-transplantation serum triglyceride
concentration was associated with post-transplantation
impaired glucose tolerance [27].
Hypertriglyceridemia is common complication in dialysis
patients. In non-transplant populations it is regarded
(along with low HDL cholesterol levels) as a prominent
feature of insulin resistance syndrome, and also is a cardi-
ovascular risk factor in organ transplant recipients [28].
Table 2: Impaired glucose tests in HD and RT recipients have higher values of serum triglyceride, serum cholesterol and cyclosporine 
concentration than patients with normal glucose tolerance tests.
no. of cases Serum 
Triglyceride(mg/dl)
Serum 
Cholesterol(mg/dl)
HbA1c (gr/l) Cyclosporine (mg/dl)
RT recipients with 
IGTT
4 231.4 ± 150 308.4 ± 24.4 7.34 ± 0.26 320.4 ± 36.6
RT Recipients With 
normal GTT
51 201 ± 75 248.7 ± 55.6 6.2 ± 0.6 295.1 ± 29
P = 0.59 P = 0.02 P = 0.001 P = 0.2
HD patients with 
IGTT
12 272.1 ± 41.3 201.1 ± 39 7 ± 1
HD patients with 
normal GTT
43 195.9 ± 45 198.5 ± 36.8 5.9 ± 0.7
P = 0.001 P = 0.87 P = 0.007
Controls 55 100.2 ± 18 190.5 ± 34 5.7 ± 0.7BMC Nephrology 2004, 5:11 http://www.biomedcentral.com/1471-2369/5/11
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Our study confirmed the relationship between impaired
glucose tolerance and triglyceride levels in HD patients,
and between impaired glucose tolerance and cholesterol
levels in RT recipients. The latter was also accompanied by
a higher level of HgA1C. Commonly used tests of HgA1C
may be unreliable in patients with end-stage renal disease
because of the presence of anemia, shortened red blood
cell survival, and assay interferences from uremia. But
HgA1C in the range of 6% to 7%, as was found in our
study, estimates glycemic control within the range of
patients without severe renal impairment [1]. So in the
range of mild to moderate increased HgA1C in HD and
uremic patients, it would be a reliable marker of impaired
glucose tolerance.
Conclusions
There was increased HgA1C and impaired glucose toler-
ance in HD and RT patients. This was accompanied by
hyperlipidemia in HD patients (with hypertriglyceri-
demia) and RT recipients (with hypercholesterolemia).
The impact upon the progression of atherosclerosis needs
more study in haemodialysis and renal transplant popula-
tions at a long term follow up.
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